DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 983,290 Shares of CME Group Inc. $CME

12 Dec 2025, 13:10 by Michael Walen · The Markets Daily

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main cut its position in shares of CME Group Inc. (NASDAQ:CME – Free Report) by 70.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 411,742 shares of the financial services provider’s stock after selling 983,290 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in CME Group were worth $113,484,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of CME Group during the 2nd quarter valued at approximately $1,571,447,000. Wellington Management Group LLP raised its stake in CME Group by 370.5% during the first quarter. Wellington Management Group LLP now owns 2,653,957 shares of the financial services provider’s stock valued at $704,068,000 after purchasing an additional 2,089,935 shares in the last quarter. Alliancebernstein L.P. lifted its position in CME Group by 185.5% during the first quarter. Alliancebernstein L.P. now owns 1,244,608 shares of the financial services provider’s stock valued at $330,182,000 after purchasing an additional 808,740 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of CME Group by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 35,176,376 shares of the financial services provider’s stock worth $9,695,313,000 after buying an additional 532,549 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. increased its holdings in shares of CME Group by 1,927.1% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 521,218 shares of the financial services provider’s stock worth $138,274,000 after buying an additional 495,505 shares during the last quarter. Institutional investors own 87.75% of the company’s stock.

CME Group Price Performance

CME opened at $272.40 on Friday. The business has a fifty day moving average of $271.68 and a 200 day moving average of $272.47. The stock has a market cap of $98.23 billion, a P/E ratio of 26.40, a PEG ratio of 4.15 and a beta of 0.28. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. CME Group Inc. has a 52-week low of $224.62 and a 52-week high of $290.79.

CME Group (NASDAQ:CME – Get Free Report) last released its earnings results on Wednesday, October 22nd. The financial services provider reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.05. The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.56 billion. CME Group had a return on equity of 14.61% and a net margin of 58.84%.The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period last year, the company earned $2.68 earnings per share. As a group, sell-side analysts anticipate that CME Group Inc. will post 10.49 EPS for the current year.

CME Group Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Friday, December 12th will be paid a $1.25 dividend. This represents a $5.00 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Friday, December 12th. CME Group’s dividend payout ratio is currently 48.45%.

Analyst Ratings Changes

CME has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of CME Group in a report on Wednesday, October 8th. Raymond James Financial decreased their price objective on CME Group from $309.00 to $307.00 and set an “outperform” rating on the stock in a research report on Monday, October 13th. The Goldman Sachs Group dropped their target price on CME Group from $264.00 to $263.00 and set a “sell” rating for the company in a report on Thursday, December 4th. Morgan Stanley boosted their target price on CME Group from $312.00 to $314.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Finally, Piper Sandler raised their price target on CME Group from $296.00 to $313.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Eight investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, CME Group currently has an average rating of “Hold” and an average price target of $288.59.

Check Out Our Latest Analysis on CME Group

Insider Activity at CME Group

In other news, Director William R. Shepard acquired 262 shares of CME Group stock in a transaction on Thursday, September 25th. The shares were bought at an average cost of $265.19 per share, for a total transaction of $69,479.78. Following the acquisition, the director directly owned 258,459 shares of the company’s stock, valued at $68,540,742.21. This trade represents a 0.10% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Jonathan L. Marcus sold 392 shares of the company’s stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $262.00, for a total value of $102,704.00. Following the completion of the sale, the general counsel owned 7,851 shares of the company’s stock, valued at $2,056,962. This represents a 4.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,147 shares of company stock valued at $562,079 over the last 90 days. 0.30% of the stock is currently owned by insiders.

CME Group Profile

(Free Report)